Janssen Targets Combinations As Next Step For Newly Approved Darzalex
This article was originally published in Scrip
Johnson and Johnson company, Janssen Research and Development, believes it can take its newly approved multiple myeloma therapy Darzalex (daratumumab) one step further by combining it with Revlimid (lenalidomide) and dexamethasone.
You may also be interested in...
Lead investigator says anti-38 antibody daratumumab compares well in earlier-stage relapsed disease to other myeloma drugs and advises using it early on the basis of "unprecedented" benefit.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.